Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High‐Dose Chemotherapy
ConclusionsThis HDC strategy led to an encouraging OS while only 20% of the patients received adjuvant RT. SHH MB, irrespective of histological subgroup, had an excellent outcome. Such intensive therapy may not be needed for this subgroup. Patients with classic histology or group 3 had an encouraging PFS of 58% and 46.4%, respectively, in the absence of adjuvant RT. The neurocognitive profile of the survivors appears to be within the normal range.
Source: Pediatric Blood and Cancer - Category: Cancer & Oncology Authors: Lucie Lafay‐Cousin, Amy Smith, Susan N. Chi, Elizabeth Wells, Jennifer Madden, Ashley Margol, Vijay Ramaswamy, Jonathan Finlay, Michael D. Taylor, Girish Dhall, Douglas Strother, Mark W. Kieran, Nicholas K. Foreman, Roger J. Packer, Eric Bouffet Tags: Research Article Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Chemotherapy | Children | Embryonal Carcinoma | Medulloblastoma | Neurology | Pediatrics